Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add filters








Language
Year range
1.
Chinese Journal of Geriatrics ; (12): 1350-1354, 2020.
Article in Chinese | WPRIM | ID: wpr-869561

ABSTRACT

Parkinson's disease combined with thyroid dysfunction is not uncommon in clinical practice.Due to similarities and overlaps between their symptoms and an unclear cause-and-effect relationship, the diagnosis and treatment may be missed and delayed.Here we summarize the clinical manifestations of the two diseases and analyze the potential pathogenic mechanisms shared between them, in order to provide a reference for the understanding of their pathogenesis and for the treatment of Parkinson's disease.

2.
Chinese Journal of Geriatrics ; (12): 1441-1444, 2019.
Article in Chinese | WPRIM | ID: wpr-824589

ABSTRACT

The theory of amyloid-induced Alzheimer's disease(AD) has been challenged by the scientific community.However,with the deep study of amyloid beta(Aβ)cascade metabolic reaction process and the characteristics and functions of various Aβ polypeptides,people have a profound understanding of the pathogenesis of AD caused by Aβ.Currently,several Aβ antibodies,including the protofibril selective antibody BAN2401,are in clinical trials for treating Alzheimer's disease.After the good results of targeted therapy for Aβ(Ban2401),this theory has attracted our attention again.In this paper,the pathogenesis of Aβ and the progress of targeted therapy were reviewed systematically.

3.
Chinese Journal of Geriatrics ; (12): 1441-1444, 2019.
Article in Chinese | WPRIM | ID: wpr-800396

ABSTRACT

The theory of amyloid-induced Alzheimer's disease(AD)has been challenged by the scientific community.However, with the deep study of amyloid beta(Aβ)cascade metabolic reaction process and the characteristics and functions of various Aβ polypeptides, people have a profound understanding of the pathogenesis of AD caused by Aβ.Currently, several Aβ antibodies, including the protofibril selective antibody BAN2401, are in clinical trials for treating Alzheimer's disease.After the good results of targeted therapy for Aβ(Ban2401), this theory has attracted our attention again.In this paper, the pathogenesis of Aβ and the progress of targeted therapy were reviewed systematically.

SELECTION OF CITATIONS
SEARCH DETAIL